Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can VR lessons help heart patients take their medicines?

NCT ID NCT07825376

Symptom relief Sponsor: Abant Izzet Baysal University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether nurse-led lessons delivered through virtual reality or a tablet help people with coronary artery disease understand their heart risks and take their antiplatelet medicines as prescribed. The trial enrolls 54 adults aged 18 to 65 who have coronary artery disease and are starting antiplatelet therapy. Participants are randomly assigned to VR education, tablet education, or routine hospital education, and researchers measure risk awareness and medication adherence before, after, and during follow-up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
branching scenario-based education delivered through virtual reality or tablet
What this could lead to
If it works, this could give hospitals a new way to teach heart patients about their risks and help them stick to antiplatelet medicines.
What could go wrong
The trial is small, with 54 participants, and it measures awareness and self-reported adherence rather than heart attacks or deaths. Better test scores may not translate into healthier habits or fewer heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-65 years. * Diagnosed with coronary artery disease. * Newly initiated on antiplatelet therapy. * Conscious and able to communicate. * Physically and cognitively able to use a virtual reality headset. * Able to read, write, and understand Turkish. * Willing to provide written informed consent. * Willing to participate in the education and follow-up process. * Has not previously received education about coronary artery disease. * Able to use a smartphone. Exclusion Criteria: * Cognitive impairment or mental illness preventing communication. * Visual or hearing impairment preventing participation in the virtual reality education. * Participation in another clinical study at the same time. * Diagnosis of malignant disease. * Bleeding disorder or active bleeding risk. * Hospitalization within the previous 3 months due to acute myocardial infarction, stroke, or another serious cardiovascular event. * Unable to understand the educational materials. * Refusal to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bolu Abant İzzet Baysal University

    Bolu, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.